Cost per response analysis of strategies for chronic immune thrombocytopenia.

CONCLUSIONS: In adults with chronic ITP, romiplostim represents an efficient way to achieve response, with lower costs per response than eltrombopag; both romiplostim and eltrombopag had lower costs per response than watch and rescue.
PMID: 30020741 [PubMed - in process]

Source: The American Journal of Managed Care - July 1, 2018 Category: Health Management Authors: Fust K, Parthan A, Li X, Sharma A, Zhang X, Campioni M, Lin J, Wang X, Zur R, Cetin K, Eisen M, Chandler D Tags: Am J Manag Care Source Type: research